IL18 and metabolic syndrome: High baseline IL-18bp, as seen in metabolic syndrome conditions [49], may prevent a sufficient rise in fIL-18 necessary to facilitate a strong Th1 response for early antigen-control, resulting in antigen escape from symptom day 15 onwards, and persistent inflammasome-mediated IL-18 release.